MedTrace Logo

A Repeatability Study of Fatty Acid Uptake Using PET/MR Imaging in Patients With T2DM and Non-diabetic Control Subjects

NCT05132335 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-08-14

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the overall variation in the assessment of fatty acid uptake and blood flow in adipose tissue and skeletal muscle in the fasted and postprandial states by evaluating the repeatability of whole-body three-dimensional kinetic (4D) combined positron emission tomography and magnetic resonance imaging (PET/MRI) readouts in participants with type 2 diabetes mellitus (T2DM), and non-diabetic control participants. Each volunteer participates 4 scanning sessions.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

OTHER

Imaging Biomarkers

One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA(\[18F\]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water(\[15O\]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements. Assigned interventions: \[18F\]-FTHA tracer injections \[15O\]-H2O tracer injections PET/MRI imaging Overnight fasting Liquid meal ingestion

Sponsors & Collaborators

  • Antaros Medical

    collaborator INDUSTRY

  • Turku University Hospital

    lead OTHER_GOV

Principal Investigators

  • Pirjo R Nuutila, MD, PhD · Turku PET Centre

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-29
Primary Completion
2021-11-25
Completion
2022-04-30

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05132335 on ClinicalTrials.gov